Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma.
Int J Cancer. 2010 May 6.
Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, Autier P.
European Institute of Oncology, Milano, Italy.
Epidemiological studies have suggested a reduced risk of several cancers associated with high vitamin D status. We performed a systematic review with meta-analyses of observational studies of serum 25-hydroxyvitamin D level and colorectal, breast and prostate cancer, and colonic adenoma. The literature to December 2009 was searched without language restriction. The meta-regression analysis was done in order to compute dose-response effects. Because in case-control studies, serum 25-hydroxyvitamin D level is measured after the diagnosis of cancer, separate analyses for case-control and prospective studies were done. We identified 35 independent studies. The seven studies on colorectal adenomas were heterogeneous in terms of endpoint and control for major confounding factors, and we did not perform a meta-analysis of these data.
The summary relative risk (SRR) and (95% confidence interval) for a 10 ng/mL increase in serum 25-hydroxyvitamin D was
0.85 (0.79; 0.91) for colorectal cancer (2630 cases in 9 studies);
0.89 (0.81;0.98) for breast cancer (6175 cases in 10 studies); and
0.99 (0.95;1.03) for prostate cancer (3956 cases in 11 studies).
For breast cancer, case-control studies (3030 cases) had major limitations and obtained SRR of 0.83 (0.79; 0.87) while SRR of prospective studies (3145 cases) was 0.97 (0.92; 1.03). For colorectal and breast cancer, differences between cases and controls in the season of blood draw or in overweight/obesity or physical inactivity could not explain the results.
In conclusion, a consistent inverse relationship between serum 25-hydroxyvitamin D levels and colorectal cancer was found.
No association was found for breast and prostate cancer. PMID: 20473927